Wells Fargo Adjusts Price Target on Halozyme Therapeutics to $58 From $48, Maintains Overweight Rating

MT NewswiresJun 7 21:21

Halozyme Downgraded at Piper Sandler Despite Guidance Raise

Seeking AlphaJun 7 21:16

Insmed Analyst Ratings

BenzingaJun 7 19:32

Jefferies Adjusts Price Target on Moderna to $180 From $155, Keeps Buy Rating

MT NewswiresJun 7 18:27

Halozyme Therapeutics Analyst Ratings

BenzingaJun 7 17:19

Piper Sandler Downgrades Halozyme Therapeutics to Neutral, Raises Price Target to $51

BenzingaJun 7 17:20

UBS Raises Price Target on Insmed to $78 From $58, Maintains Buy Rating

MT NewswiresJun 6 00:18

Insmed Analyst Ratings

BenzingaJun 5 21:21

Twist Bioscience Analyst Ratings

BenzingaJun 5 18:02

Guggenheim Initiates Twist Bioscience With Buy Rating, $53 Price Target

MT NewswiresJun 4 18:44

Halozyme Therapeutics Analyst Ratings

BenzingaJun 4 18:27

HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $50 Price Target

BenzingaJun 4 18:28

Natera Analyst Ratings

BenzingaJun 4 02:10

Jefferies Initiates Coverage On Natera With Buy Rating, Announces Price Target of $142

BenzingaJun 4 02:12

Moderna Analyst Ratings

BenzingaJun 4 01:37

RBC Capital Maintains Outperform on Moderna, Raises Price Target to $160

BenzingaJun 4 01:39

Needham: Reiterates that Moderna (MRNA.US) holds the rating.

Zhitong FinanceJun 3 17:40

Moderna Analyst Ratings

BenzingaJun 3 17:33

Moderna: Royal Bank of Canada raised the target price from $135 to $160

Zhitong FinanceJun 3 14:40

Natera Inc.: Jefferies launches report with a buy rating; target share price is $142

Zhitong FinanceJun 3 13:42